View Older Stories View More Recent Stories
-
BMO Capital Starts Freeport-McMoRan (FCX) at Market Perform
-
BMO Capital Starts Constellium (CSTM) at Market Perform
-
BMO Capital Starts CONSOL Energy (CNX) at Outperform
-
BMO Capital Starts Cloud Peak Energy (CLD) at Market Perform
-
BMO Capital Starts Century Aluminum (CENX) at Outperform
-
BMO Capital Starts Peabody Energy (BTU) at Market Perform
-
BMO Capital Starts Alpha Natural Resources (ANR) at Underperform
-
BMO Capital Starts AK Steel (AKS) at Market Perform
-
BMO Capital Starts Arch Coal Inc (ACI) at Underperform
-
BMO Capital Starts Alcoa (AA) at Market Perform
-
Zoetis (ZTS) Abbott Deal Seen as 'Good', BMO Capital Says; Focus Remains on Takeover Prospects (VRX)
-
Rocket Fuel to Present at Upcoming Investor Conferences
-
Receptos (RCPT) Reports Proposed Offering of Common Stock
-
Valeant Pharmaceuticals (VRX) Looking Past Allergan - BMO Capital
-
Apple (AAPL) Gains on Bullish Analyst Commentary
-
BMO Capital Downgrades Boise Cascade Company (BCC) to Market Perform
-
Notable Analyst Rating Changes 11/14: (RTN) (ESRT) (GERN) Upgraded; ((TJX) (LULU) (WMT) Downgraded
-
BMO Capital Downgrades Wal-Mart (WMT) to Underperform
-
Notable Analyst Rating Changes 11/13: (GNW) (AMAT) (BRCM) Upgraded; (MRVL) (M) (BMY) Downgraded
-
Memorial Resource Development (MRD) Prices 30M Common Secondary Offering at $23/Share
-
BMO Capital Upgrades Rosetta Resources (ROSE) to Outperform
-
BMO Capital Downgrades Laredo Petroleum (LPI) to Market Perform
-
Memorial Resource Development Corp. Announces Pricing of Secondary Public Offering of Common Stock
-
BMO Capital Retains Bullish Stance on Intercept Pharmaceuticals (ICPT) Following Q3 Results, FLINT Data
-
BMO Capital Downgrades REX Energy (REXX) to Market Perform
-
Whitestone REIT Increases Unsecured Credit Facility to $500 Million
-
Notable Analyst Rating Changes 11/7: (CA) (GNC) (SPLK) Upgraded; (OXY) (ABBV) (SLXP) Downgraded
-
UPDATE: BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Walt Disney (DIS) PT Lifted to $100 at BMO Capital Following Q4 Results
-
Balanced Intercept (ICPT) FLINT Review Will Leave Near-Term Debate, BMO Capital Says
-
The Chefs' Warehouse (CHEF) PT, Estimates Lowered at BMO Capital
-
CBS (CBS) Q3 Results 'Positive', BMO Says
-
BMO Capital Downgrades Hormel Foods (HRL) to Market Perform
-
Regulus Therapeutics (RGLS) Price Target Raised to $34 at BMO; Could Attract Interest from Big Pharma, Says Analyst
-
BMO Capital Downgrades Sapient (SAPE) to Market Perform Amid Takeover
-
BMO Capital Downgrades Tornier (TRNX) to Market Perform
-
BMO Capital Upgrades Intrepid Potash (IPI) to Market Perform
-
BMO Capital Keeps Arena Pharma (ARNA) at 'Market Perform' Following BELVIQ Combo Update
-
Facebook (FB) Results Neutral Overall, Negative vs Expectations - BMO Capital
-
BMO Capital Downgrades Parker-Hannifin (PH) to Market Perform
-
Regulus Therapeutics (RGLS) 5.29M Offering Prices at $17/Share
-
Unusual 11 Mid-Day Movers 10/28: (RCPT) (VDSI) (SANM) Higher; (IBIO) (AMKR) (DCO) Lower
-
Receptos (RCPT) PT Raised to $125 at BMO Capital on Results
-
Twitter (TWTR) Results Neutral Overall, Negative Versus Expectations - BMO Capital; PT Cut to $46
-
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
-
Regulus Therapeutics (RGLS) Reports $80M Common Stock Offering
-
Regulus Therapeutics (RGLS) Announces $80M Common Stock Offering
-
BMO Capital Starts Civitas Solutions (CIVI) at Outperform
-
Notable Analyst Rating Changes 10/24: (MXIM) (CHKP) (HAL) Upgraded; (ANF) (CAB) (AEO) Downgraded
-
BMO Capital Starts Alibaba (BABA) at Outperform


